India’s drug price regulator has told manufacturers, retailers and hospitals to strictly follow revised maximum retail prices (MRPs) for 137 non-scheduled anti-cancer drugs, warning that violations will invite overcharging proceedings.
In an office memorandum issued on November 11, the National Pharmaceutical Pricing Authority (NPPA) said the revised prices took effect on November 9.
The memorandum has directed all manufacturers, retailers, dealers, stockists, hospitals and medical institutions to comply with the revised prices. Violations will trigger overcharging proceedings under the Drugs (Prices Control) Order, 2013.
Every retailer, dealer, hospital and medical institution must prominently display the revised price lists at their premises and on their websites, as required under the order. Hospitals and medical institutions must also monitor the MRPs of formulations to ensure compliance.
“State Drug Controllers (SDCs) have been directed to strictly monitor compliance by manufacturers, dealers, hospitals and medical institutions to ensure that the benefits of revised MRPs are passed on to patients. Any violation may attract overcharging proceedings under the provisions of DPCO, 2013,” said the order.
Patients and others can report overcharging, shortages or non-availability through the Pharma Sahi Daam app and portal, the helpline 1800-111-255, or by email to [email protected].
Published on November 13, 2026
